AI assistant
IXICO PLC — Director's Dealing 2016
Feb 4, 2016
7723_dirs_2016-02-04_a978e398-8156-4512-b756-e5a34140dc95.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 0098O
IXICO plc
04 February 2016
4 February 2016
IXICO plc Director's dealings
4 February 2016, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company'), the brain health company, announces that it was notified on 3 February 2016 that, on the same day, Dr Andrew Richards, Non-Executive Chairman of the Company, purchased 45,899 Ordinary Shares of 1p each in IXICO at a price of 32.68p pence per Ordinary Share through his self-invested pension plan ("SIPP"), of which he is the sole beneficiary. As a consequence of this share purchase, Dr Andrew Richards is beneficially interested in 76,099 Ordinary Shares representing 0.29% of the Company's issued share capital.
Enquiries:
| IXICO plc | +44 20 3763 7499 |
| Derek Hill, CEO | |
| Susan Lowther, CFO | |
| Peel Hunt LLP (Nominated Adviser and Broker) | +44 20 7418 8900 |
| James Steel / Oliver Jackson | |
| Daniel Stewart & Company (Joint Broker) | +44 207 776 6550 |
| Martin Lampshire / David Coffman | |
| FTI Consulting Limited (Investor Relations) | +44 20 3727 1000 |
| Simon Conway / Mo Noonan / Matthew Moss |
Notes to Editors
About IXICO
IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes.
The Company's brain health focus includes Alzheimer's disease, Huntington's disease, Multiple Sclerosis, behavioural health, child and adolescent mental health.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSDXLFBQLFXBBB